Article Text

Download PDFPDF
Does providing laboratory confirmed STI results impact uptake of HIV pre-exposure prophylaxis (PrEP) uptake among Kenyan adolescents girls and young women? A descriptive analysis
  1. Lynda Myra Oluoch1,
  2. Alison Roxby2,
  3. Nelly Mugo1,2,
  4. Anna Wald3,4,
  5. Kenneth Ngure5,
  6. Stacy Selke2,
  7. Bhavna Chohan2,
  8. Catherine Kiptinness1,
  9. Kenneth Tapia2,
  10. Murugi Micheni1,
  11. Stephen Gakuo Maina1,
  12. Edinah Casmir1
  1. 1 Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
  2. 2 Department of Global Health, University of Washington, Seattle, Washington, USA
  3. 3 Department of Medicine, University of Washington, Seattle, Washington, USA
  4. 4 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  5. 5 Department of Community Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya
  1. Correspondence to Dr Lynda Myra Oluoch, Clinic, Kenya Medical Research Institute, Nairobi 0200, Kenya; oluochlynda8{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In 2018, one-third of incident adult HIV infections in Kenya occurred among adolescent girls and young women (AGYW) aged 15–24 years.1 2 Pre-exposure prophylaxis (PrEP) is approved as part of the national HIV prevention interventions.3 4 AGYW have the lowest uptake of PrEP coupled with high discontinuation rates.5–7

Sexually transmitted infections are known to increase the risk of HIV acquisition.8 Prevalence of STIs in sexually active AGYW is high.9 This drives health seeking behaviour in this population and is a good opportunity to provide PrEP at point of care.

We hypothesised that availing STI results would augment PrEP uptake among AGYW.

Participants were followed quarterly with STI testing for Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis. From January 2018 to December 2018, we screened for PrEP eligibility with a validated HIV risk assessment …

View Full Text


  • Handling editor Anna Maria Geretti

  • Contributors LMO conceptualised the idea for the abstract and participated in its design and coordination together with AR, NM, KN, CK and AW to draft the manuscript. SS, KT and SGM performed the data statistical analysis. MM, EC and LMO were involved in the data collection. BC participated in the lab analysis. All authors read and approved the final manuscript.

  • Funding This research was funded by R01 HD091996-01 (ACR) from NICHD, by P01 AI 030731-25 (Project 2) (AW) and by the University of Washington/Fred Hutchinson Cancer Research Center, Center for AIDS Research (CFAR), AI027757. We thank the participants. We thank CROI for scholarship funding that enabled us to present this data at the CROI Seattle 2019 conference. Study data were collected and managed using REDCap electronic data capture tools hosted at the University of Washington funded by UL1 TR002319, KL2 TR002317 and TL1 TR002318 from NCATS/NIH.

  • Disclaimer The funders had no role in study design, data collection and analysis or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.